{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:37:54Z","timestamp":1791005874751,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"10","funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,8,10]]},"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To establish a unique sample of proarrhythmia cases, determine the characteristics of cases and estimate the contribution of individual drugs to the incidence of proarrhythmia within these cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Suspected proarrhythmia cases were referred by cardiologists across England between 2003 and 2011. Information on demography, symptoms, prior medical and drug histories and data from hospital notes were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Two expert cardiologists reviewed data for 293 referred cases: 130 were included. Inclusion criteria were new onset or exacerbation of pre-existing ventricular arrhythmias, QTc &gt;500\u2009ms, QTc &gt;450\u2009ms (men) or &gt;470\u2009ms (women) with cardiac syncope, all secondary to drug administration. Exclusion criteria were acute ischaemia and ischaemic polymorphic ventricular tachycardia at presentation, structural heart disease, consent withdrawn or deceased prior to study. Descriptive analysis of Caucasian cases (95% of included cases, n=124) and culpable drug exposures was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 124 Caucasian cases, 95 (77%) were QTc interval prolongation-related; mean age was 62 years (SD 15), and 63% were female. Cardiovascular comorbidities included hypertension (53%) and patient-reported \u2018heart rhythm problems\u2019 (73%). Family history of sudden death (36%) and hypokalaemia at presentation (27%) were common. 165 culpable drug exposures were reported, including antiarrhythmics (42%), of which amiodarone and flecainide were the most common. Sotalol, a beta-blocking agent with antiarrhythmic activity, was also common (15%). 26% reported multiple drugs, of which 84% reported at least one cytochrome (CYP) P450 inhibitor. Potential pharmacodynamics interactions identified were mainly QT prolongation (59%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antiarrhythmics, non-cardiac drugs and drug combinations were found to be culpable in a large cohort of 124 clinically validated proarrhythmia cases. Potential clinical factors that may warn the prescriber of potential proarrhythmia include older women, underlying cardiovascular comorbidity, family history of sudden death and hypokalaemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-016627","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T22:15:49Z","timestamp":1508192149000},"page":"e016627","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort"],"prefix":"10.1136","volume":"7","author":[{"given":"Abigail L","family":"Coughtrie","sequence":"first","affiliation":[{"name":"Research Department, Drug Safety Research Unit, Southampton, UK"},{"name":"School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah R","family":"Behr","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group, St George\u2019s University of London, London, UK"},{"name":"Cardiology Clinical Academic Group, St George\u2019s University Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Layton","sequence":"additional","affiliation":[{"name":"Research Department, Drug Safety Research Unit, Southampton, UK"},{"name":"School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Marshall","sequence":"additional","affiliation":[{"name":"Research Department, Drug Safety Research Unit, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group, St George\u2019s University of London, London, UK"},{"name":"Cardiology Clinical Academic Group, St George\u2019s University Hospitals NHS Foundation Trust, London, UK"},{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad A W","family":"Shakir","sequence":"additional","affiliation":[{"name":"Research Department, Drug Safety Research Unit, Southampton, UK"},{"name":"School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"2025121400064015000_7.10.e016627.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi312"},{"key":"2025121400064015000_7.10.e016627.2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90708-O"},{"key":"2025121400064015000_7.10.e016627.3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(88)90136-1"},{"key":"2025121400064015000_7.10.e016627.4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157488610789869157","article-title":"Endocrine therapies and QTc prolongation","volume":"5","author":"Gonzalez","year":"2010","journal-title":"Curr Drug Saf"},{"key":"2025121400064015000_7.10.e016627.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270106"},{"key":"2025121400064015000_7.10.e016627.6","first-page":"1657","article-title":"QTc interval prolongation in patients with HIV and AIDS","volume":"97","author":"Sani","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"2025121400064015000_7.10.e016627.7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2015.00026","article-title":"Long QT syndrome: an emerging role for inflammation and immunity","volume":"2","author":"Lazzerini","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"2025121400064015000_7.10.e016627.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.009800"},{"key":"2025121400064015000_7.10.e016627.9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pace.13040","article-title":"Evaluation of prolonged QT interval: structural heart disease mimicking long QT syndrome","volume":"40","author":"Weissler-Snir","year":"2017","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025121400064015000_7.10.e016627.10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/archinte.1955.00250160060005","article-title":"The electrocardiogram in electrolyte imbalance","volume":"96","author":"Bellet","year":"1955","journal-title":"AMA Arch Intern Med"},{"key":"2025121400064015000_7.10.e016627.11","doi-asserted-by":"publisher","DOI":"10.1159\/000078850"},{"key":"2025121400064015000_7.10.e016627.12","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225040-00004"},{"key":"2025121400064015000_7.10.e016627.13","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612454283"},{"key":"2025121400064015000_7.10.e016627.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00119-X"},{"key":"2025121400064015000_7.10.e016627.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(83)80226-5"},{"key":"2025121400064015000_7.10.e016627.16","doi-asserted-by":"publisher","DOI":"10.1038\/74793"},{"key":"2025121400064015000_7.10.e016627.17","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.96.1.195"},{"key":"2025121400064015000_7.10.e016627.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.031"},{"key":"2025121400064015000_7.10.e016627.19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000027139.42087.B6"},{"key":"2025121400064015000_7.10.e016627.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-003-0522-z"},{"key":"2025121400064015000_7.10.e016627.21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs351"},{"key":"2025121400064015000_7.10.e016627.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510210076031"},{"key":"2025121400064015000_7.10.e016627.23","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1363"},{"key":"2025121400064015000_7.10.e016627.24","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.10.2535"},{"key":"2025121400064015000_7.10.e016627.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70177-5"},{"key":"2025121400064015000_7.10.e016627.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2215"},{"key":"2025121400064015000_7.10.e016627.27","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90006-X"},{"key":"2025121400064015000_7.10.e016627.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03927.x"},{"key":"2025121400064015000_7.10.e016627.29","unstructured":"ICH. Harmonized Tripartite Guideline E14: The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. 2005."},{"key":"2025121400064015000_7.10.e016627.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.02.020"},{"key":"2025121400064015000_7.10.e016627.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-0620(05)80005-2"},{"key":"2025121400064015000_7.10.e016627.32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000152"},{"key":"2025121400064015000_7.10.e016627.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-008-0741-y"},{"key":"2025121400064015000_7.10.e016627.34","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1280"},{"key":"2025121400064015000_7.10.e016627.35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12060860"},{"key":"2025121400064015000_7.10.e016627.36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0002-9149(90)90207-H","article-title":"Clinical safety profile of sotalol in patients with arrhythmias","volume":"65","author":"Soyka","year":"1990","journal-title":"Am J Cardiol"},{"key":"2025121400064015000_7.10.e016627.37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-7-199410010-00009"},{"issue":"Suppl 4","key":"2025121400064015000_7.10.e016627.38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00003495-198500294-00010","article-title":"The proarrhythmic effects of flecainide","volume":"29","author":"Nathan","year":"1985","journal-title":"Drugs"},{"key":"2025121400064015000_7.10.e016627.39","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut214"},{"key":"2025121400064015000_7.10.e016627.40","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-4-1"},{"key":"2025121400064015000_7.10.e016627.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.07.761"},{"key":"2025121400064015000_7.10.e016627.42","doi-asserted-by":"crossref","unstructured":"Vandael E , Vandenberk B , Vandenberghe J , et al . Cases of drug-induced torsade de pointes: a review of belgian cases in the eudravigilance database. Acta Clin Belg 2017:1\u20136.doi:10.1080\/17843286.2017.1300217","DOI":"10.1080\/17843286.2017.1300217"},{"key":"2025121400064015000_7.10.e016627.43","unstructured":"Behr ER . Inherited heart conditions:\u00a0Sudden arrhythmic death syndrome. 2009. https:\/\/www.bhf.org.uk\/-\/media\/files\/publications\/heart-conditions\/m111a-life-with-sudden-arrhythmic-death-syndrome.pdf."},{"key":"2025121400064015000_7.10.e016627.44","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"2025121400064015000_7.10.e016627.45","doi-asserted-by":"publisher","DOI":"10.4065\/78.12.1479"},{"key":"2025121400064015000_7.10.e016627.46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2004.03534.x"},{"key":"2025121400064015000_7.10.e016627.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078511","article-title":"Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes","volume":"8","author":"Behr","year":"2013","journal-title":"PLoS One"},{"key":"2025121400064015000_7.10.e016627.48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.111.960930"},{"key":"2025121400064015000_7.10.e016627.49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7243.1158"},{"key":"2025121400064015000_7.10.e016627.50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(05)73412-7","article-title":"QTc and psychotropic drugs","volume":"356","author":"De Ponti","year":"2000","journal-title":"Lancet"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-016627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:06:48Z","timestamp":1765699608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-016627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,16]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/bmjopen-2017-016627"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-016627","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}